Intravitreal bevacizumab during pregnancy

Ryan M Tarantola; James C Folk; H Culver Boldt; Vinit B Mahajan

doi:10.1097/IAE.0b013e3181f57d58

Back

Intravitreal bevacizumab during pregnancy

Journal article

Peer reviewed

Intravitreal bevacizumab during pregnancy

Ryan M Tarantola, James C Folk, H Culver Boldt and Vinit B Mahajan

Retina (Philadelphia, Pa.), Vol.30(9), pp.1405-1411

10/2010

DOI: 10.1097/IAE.0b013e3181f57d58

PMID: 20924262

View Online

Abstract

To report the clinical course of four women treated with intravitreal bevacizumab during pregnancy. Observational case series. Four pregnant women were treated with intravitreal bevacizumab for choroidal neovascularization (CNV) because of presumed ocular histoplasmosis syndrome punctate inner choroidopathy, or sarcoid uveitis. Patients received a mean of 2.6 ± 2.3 injections (range, 1-6 injections) while pregnant. One patient was treated with five additional injections while breastfeeding. The mean follow-up duration after the most recent injection was 14 ± 2.9 months (range, 11-18 months). Snellen visual acuity improved in all 4 patients with a mean of 5.75 ± 2.2 lines (range, 3-8 lines). At the most recent follow-up, all patients had involuted CNV that did not require additional treatment. All patients had an uneventful prenatal course and delivered healthy full-term infants. All children have remained healthy, exhibiting normal development and growth during infancy. Offering pregnant patients intravitreal bevacizumab therapy during pregnancy for off-label ocular indications can result in significant visual improvement. No adverse events related to treatment occurred in any patient included in this study. Additional studies with more patients and longer follow-up duration are required to identify any risks associated with treatment.

Choroidal Neovascularization - diagnosis

Off-Label Use

Follow-Up Studies

Intravitreal Injections

Tomography, Optical Coherence

Humans

Pregnancy Complications

Choroidal Neovascularization - etiology

Eye Infections, Fungal - complications

Vascular Endothelial Growth Factor A - antagonists & inhibitors

Gestational Age

Histoplasmosis - complications

Bevacizumab

Pregnancy

Antibodies, Monoclonal, Humanized

Sarcoidosis - complications

Angiogenesis Inhibitors - administration & dosage

Choroidal Neovascularization - drug therapy

Antibodies, Monoclonal - administration & dosage

Adult

Female

Uveitis - complications

Visual Acuity - physiology

Details

Title: Subtitle: Intravitreal bevacizumab during pregnancy
Creators: Ryan M Tarantola - Vitreoretinal Service, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa, USA
James C Folk
H Culver Boldt
Vinit B Mahajan
Resource Type: Journal article
Publication Details: Retina (Philadelphia, Pa.), Vol.30(9), pp.1405-1411
Publisher: United States
DOI: 10.1097/IAE.0b013e3181f57d58
PMID: 20924262
ISSN: 0275-004X
eISSN: 1539-2864
Language: English
Date published: 10/2010
Academic Unit: Stead Family Department of Pediatrics; Ophthalmology and Visual Sciences
Record Identifier: 9983980084002771

Metrics

18 Record Views

63 Times Cited - Web of Science

See more details